Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
545 JPY | -0.91% | +2.06% | -59.18% |
2023 | SUSMED,Inc.(TSE:4263) added to S&P Global BMI Index | CI |
2022 | Walgreens Boots Alliance, Inc. Joins Sustainable Medicines Partnership | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Ratings chart - Surperformance
Sector: IT Services & Consulting
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-59.18% | 58.93M | - | ||
-13.47% | 191B | A- | ||
+1.02% | 166B | B+ | ||
+6.07% | 159B | B- | ||
+8.23% | 103B | A- | ||
+36.82% | 84.49B | C- | ||
+11.07% | 82.27B | A- | ||
-5.71% | 71.3B | A | ||
-18.24% | 54.34B | C | ||
-8.39% | 43.63B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 4263 Stock
- Ratings SUSMED,Inc.